AIM ImmunoTech Inc
AIM2.680USD
+0.070+2.68%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
2.05MValor de mercado
PerdaP/L TTM
Mais detalhes de AIM ImmunoTech Inc Empresa
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
Informações da empresa
Código da empresaAIM
Nome da EmpresaAIM ImmunoTech Inc
Data de listagemJul 12, 1996
CEOMr. Thomas K. Equels, Esq., J.D.
Número de funcionários21
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 12
Endereço2117 Sw Highway 484
CidadeOCALA
Bolsa de valoresThe Toronto Stock Exchange
PaísUnited States of America
Código postal32801
Telefone13524487797
Sitehttps://aimimmuno.com/
Código da empresaAIM
Data de listagemJul 12, 1996
CEOMr. Thomas K. Equels, Esq., J.D.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.88K
+0.54%
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
19.70K
+196850.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+60.53%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
+31.96%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
642.00
+232.64%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.88K
+0.54%
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
19.70K
+196850.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
+60.53%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
+31.96%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
642.00
+232.64%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: sáb, 16 de ago
Atualizado em: sáb, 16 de ago
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Equels (Thomas K)
1.44%
Kellner (Theodore D)
0.73%
Deutsch (Todd A)
0.63%
Corient Private Wealth LLC
0.37%
Mitchell (William M)
0.19%
Outro
96.64%
Investidores
Investidores
Proporção
Equels (Thomas K)
1.44%
Kellner (Theodore D)
0.73%
Deutsch (Todd A)
0.63%
Corient Private Wealth LLC
0.37%
Mitchell (William M)
0.19%
Outro
96.64%
Tipos de investidores
Investidores
Proporção
Individual Investor
3.41%
Investment Advisor/Hedge Fund
0.37%
Investment Advisor
0.08%
Outro
96.14%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
68
134.81K
4.88%
-27.49K
2025Q1
83
99.85K
13.13%
-1.64M
2024Q4
79
10.59M
16.61%
-4.59M
2024Q3
75
14.47M
24.79%
+767.12K
2024Q2
74
13.00M
23.76%
+4.07M
2024Q1
77
8.58M
17.30%
-354.68K
2023Q4
77
8.35M
17.07%
-576.60K
2023Q3
80
8.49M
17.46%
-718.46K
2023Q2
77
5.43M
11.23%
-869.40K
2023Q1
81
5.73M
11.83%
-1.19M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Equels (Thomas K)
38.88K
5.09%
+210.00
+0.54%
Jun 13, 2025
Kellner (Theodore D)
19.70K
2.58%
+19.68K
+196850.00%
Apr 11, 2025
Deutsch (Todd A)
17.16K
2.25%
--
--
Dec 19, 2024
Mitchell (William M)
5.22K
0.68%
+1.97K
+60.53%
Apr 11, 2025
Rodino (Peter W III)
4.02K
0.53%
+5.00
+0.12%
Apr 04, 2025
Appelrouth (Stewart L.)
3.89K
0.51%
+670.00
+20.82%
Dec 31, 2024
Bryan (Nancy K)
2.92K
0.38%
+707.00
+31.96%
Mar 24, 2025
Morgan Stanley Smith Barney LLC
763.00
0.1%
--
--
Mar 31, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Mar 03, 2025
Merger
100→1
Data
Tipo
Proporção
Mar 03, 2025
Merger
100→1
